City branding as economic necessity

Kvalitetno brendiranje grada je preduvjet za njihovu prepoznatljivost, kvalitetno pozicioniranje i stvaranje dodatne vrijednosti. Praksa i mnogobrojni primjeri potvrđuju ispravnost ove teze. Brendiranje gradova je nužno kako bi se pojačala konkurentnost, ostvarila veća dobit i osigurao razvoj mjesta. No ne radi se samo o ekonomskim kategorijama jer se pod razvojem mjesta podrazumijevaju i pozitivna demografska kretanja, obogaćivanje kulturnih sadržaja kao i drugih činitelja koji podižu ukupnu kvalitetu života. Izazov je to i nužnost i za gradove u Hrvatskoj kako bi bili konkurentni u oštroj tržišnoj konkurenciji.Quality city branding is a precondition for their recognazibility, quality positionig and creating of added value. Practice and numerous examples confirm correction of this theses. City branding is necessary to enhance concurence, gain bigger profit and ensure place development. But this is not only about economic categories because under place development it is understandable alsto positive demographic movement, enrichment of cultural contens as well as other factors which raise total quality of life. This is as well a challenge as it is a necessity for cities in Croatia so they could be concurente in harsh economy concurence

Nachweis und Interpretation von Grundwasserschwankungen in einem flussnahen Trinkwasserfördergebiet mittels multivariater Analyse

Hydrogeologie der Nordwestschweiz, Grundwasse

Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).

PURPOSE: The EGF receptor (EGFR) is overexpressed in the majority of metastatic castration-resistant prostate cancers (mCRPC) and might represent a valid therapeutic target. The combination of docetaxel and cetuximab, the monoclonal antibody against EGFR, has not been tested in patients with prostate cancer. EXPERIMENTAL DESIGN: Patients with mCRPC progressing during or within 90 days after at least 12 weeks of docetaxel were included in this phase II trial. Treatment consisted of docetaxel (75 mg/m(2) every 3 weeks or 35 mg/m(2) on days 1, 8, 15 every 4 weeks) in combination with cetuximab (400 mg/m(2) on day 1 and then 250 mg/m(2) weekly). The primary endpoint was progression-free survival (PFS) at 12 weeks defined as the absence of prostate-specific antigen (PSA), radiographic, or clinical progression. Evaluation of known biomarkers of response and resistance to cetuximab (EGFR, PTEN, amphiregulin, epiregulin) was conducted. RESULTS: Thirty-eight patients were enrolled at 15 Swiss centers. Median age was 68 years and median PSA was 212 ng/mL. PFS at 12 weeks was 34% [95% confidence interval (CI), 19%-52%], PFS at 24 weeks was 20%, and median overall survival (OS) was 13.3 months (95% CI, 7.3-15.4). Seven patients (20%) had a confirmed ≥ 50% and 11 patients (31%) a confirmed ≥ 30% PSA decline. About 47% of enrolled patients experienced grade 3 and 8% grade 4 toxicities. A significantly improved PFS was found in patients with overexpression of EGFR and persistent activity of PTEN. CONCLUSIONS: EGFR inhibition with cetuximab might improve the outcome of patients with mCRPC. A potential correlation between EGFR overexpression, persistent expression of PTEN, and EGFR inhibition should be investigated further